Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination—of irinotecan, ...
Dec 24, 2020
0
15
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
5
The absence of a protein that works to prevent tumor formation may explain why some patients are resistant to a common cancer therapy, according to Penn State College of Medicine researchers. They said that testing cancers ...
Dec 21, 2020
0
13
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
A study led by researchers at the University of Kentucky Markey Cancer Center highlighted differences in patient diagnosis and treatment in those with non-small cell lung cancer (NSCLC) across the state of Kentucky.
Sep 23, 2020
0
0
According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment.
Aug 12, 2020
0
232
More than 200 genes with novel and known roles in glioblastoma—the most aggressive type of brain cancer—offer promising new drug targets. Researchers from the Wellcome Sanger Institute, Addenbrooke's Hospital and their ...
Jul 29, 2020
0
176
Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous ...
Feb 7, 2020
0
1
Targeted, highly effective cancer treatments often produce debilitating side effects. This is the case with one commonly used therapy which works by blocking the epidermal growth factor receptor (EGFR), a protein that stimulates ...
Dec 12, 2019
0
68
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ...
Aug 19, 2019
0
3
